Shimadzu Announces the Start of Its Blood-Based Amyloid Mass Spectrometry Service Dedicated to Drug Discovery and Development November 19, 2020November 19, 2020 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: Shimadzu Customer Service Center Established to…Shimadzu Introduces iMScope™ QT Imaging Mass…Roche's Elecsys Amyloid Plasma Panel granted…Antibody monitoring technology using mass…Bruker Launches New timsTOF-based MALDI PharmaPulse®…Drug Discovery Platform Solutions Using JEOL’s 800 MHz NMR!
